Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: A Belgian retrospective multicentric study

Journal of Internal Medicine

Volumn 266, Issue 5, 2009, Pages 484-491

  Dierickx, D ^a   Verhoef, G ^a   Van Hoof, A ^b   Mineur, P ^c   Roest, A ^d   Triffet, A ^e   Kentos, A ^f   Pierre, P ^g   Boulet, D ^h   Bries, G ⁱ   Le P Q ^j   Janssens, A ^a   Delannoy, A ^k  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Algemeen Ziekenhuis St Jan   (Switzerland)

^c Department of Oncology Haematology   (United States)

^d ZNA Stuyvenberg ^*  (Belgium)

^e Centre Hospitalier Universitaire de Charleroi   (Belgium)

^f ERASME HOSPITAL   (Belgium)

^g Cliniques du Sud Luxembourg   (Belgium)

^h Clinique Saint Joseph at Mons   (Belgium)

ⁱ VIRGA JESSE HOSPITAL   (Belgium)

^j UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

Auto immune haemolytic anaemia; CD 20; Immune thrombocytopenic purpura; Monoclonal antibody; Rituximab

Indexed keywords

CORTICOSTEROID; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNITY; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HEMOLYTIC ANEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFANT; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUESTIONNAIRE; RETREATMENT; RETROSPECTIVE STUDY; SPLENECTOMY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BELGIUM; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349880827     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02126.x     Document Type: Article

References (43)

1. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002 69 : 258 271.
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002 346 : 995 1008.
3. Berentsen S, Beiske K, Tjonnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology 2007 12 : 361 370.
4. Mazzucconi MG, Fazi P, Bernasconi S et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007 109 : 1401 1407.
5. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 88 : 3 40.
6. Sailler L. Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks. Clin Rev Allergy Immunol 2008 34 : 103 110.
7. Quartier P, Brethon B, Philippet P et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001 358 : 1511 1513.
8. Gupta N, Kavuru S, Patel D et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002 16 : 2092 2095.
9. Shanafelt TD, Madueme HL, Wolf RC et al. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolyic anemia, and Evans syndrome. Mayo Clin Proc 2003 78 : 1340 1346.
10. Trapè G, Fianchi L, Lai M et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003 88 : 223 224.
11. Zecca M, Nobili B, Ramenghi U et al. Rituximab for treatment of refractory autoimmune hemolytic anemia in children. Blood 2003 101 : 3857 3861.
12. Zaja F, Vianelli N, Sperotto A et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003 44 : 1951 1955.
13. Berentsen S, Ulvestad E, Gjertsen BT et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004 103 : 2925 2928.
14. Narat S, Gandla J, Hoffbrand AV et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 2005 90 : 1273 1274.
15. Schöllkopf C, Kjeldsen L, Bjerrum OW et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006 47 : 253 260.
16. D'Arena G, Laurenti L, Capalbo S et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006 81 : 598 602. (Pubitemid 44066170)
17. Berentsen S, Ulvestad E, Langholm R et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006 91 : 460 466.
18. D'Arena G, Califano C, Annunziata M et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia : a retrospective study of 11 adult patients. Eur J Haematol 2007 79 : 53 8.
19. Rao A, Kelly M, Musselman M et al. Safety, efficacy and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008 50 : 822 825.
20. Bussone G, Ribeiro E, Dechartres A et al. Efficacy and safety of rituximab in adult's warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol 2009 84 : 153 157.
21. Saleh MN, Gutheil J, Moore M et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000 27 (Suppl 12 99 103.
22. Stasi R, Pagano A, Stipa E et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001 98 : 952 957.
23. Giagounidis AA, Anhuf J, Schneider P et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002 69 : 95 100.
24. Narang M, Penner JA, Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol 2003 74 : 263 267.
25. Zaja F, Vianelli N, Sperotto A et al. The B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003 88 : 538 546.
26. Cooper N, Stasi R, Cunningham-Rundles S et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004 125 : 232 239.
27. Braendstrup P, Bjerrum OW, Nielsen OJ et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005 78 : 275 280.
28. Zaja F, Vianelli N, Battista M et al. Earlier administration of rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006 34 : 571 572.
29. Penalver FJ, Jiménez-Yuste V, Almagro M et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006 85 : 400 406.
30. Scheinberg M, Hamerschlak N, Kutner JM et al. Rituximab in refractory auto-immune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 2006 24 : 65 9.
31. Schweizer C, Reu FJ, Ho AD et al. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Ann Hematol 2007 86 : 711 717.
32. Garcia-Chaves J, Majluf-Cruz A, Montiel-Cervantes L et al. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura : a long-term follow-up analysis. Ann Hematol 2007 86 : 871 877.
33. Provan D, Butler T, Evangelista ML et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007 92 : 1695 1698.
34. Godeau B, Porcher R, Fain O et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008 112 : 999 1004.
35. Pasa S, Altintas A, Cil T et al. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocytopenic purpura. J Thromb Thrombolysis 2009 27 : 329 333.
36. Zaja F, Battista ML, Pirrotta MT et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008 93 : 930 933.
37. Fairweather H, Tuckfield A, Grigg A. Abbreviated dose rituximab for immune-mediated haematological disorders. Am J Hematol 2008 83 : 554 557.
38. Medeot M, Zaja F, Vianelli N et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long- term follow-up results. Eur J Haematol 2008 81 : 165 169.
39. Zaja F, Baccarani M, Mazza P et al. A prospective randomized study comparing rituximab and dexamethasone versus dexamethasone alone in ITP: results of final analysis and long term follow up (ASH annual meeting abstracts). Blood 2008 112 : abstract 1.
40. Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica 2008 93 : 98 103.
41. Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an International Working Group. Blood 2009 113 : 2386 2393.
42. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008 141 : 149 169.
43. Perrotta AL. Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. Clin Appl Thromb Hemost 2006 12 : 97 100.